S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)

DICE Therapeutics (DICE) Price Target & Analyst Ratings

$32.96
+0.38 (+1.17%)
(As of 06/9/2023 ET)
Compare
Today's Range
$32.00
$33.08
50-Day Range
$25.86
$38.24
52-Week Range
$12.64
$45.99
Volume
338,294 shs
Average Volume
456,772 shs
Market Capitalization
$1.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$62.60

DICE Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 11 Analyst Ratings

Consensus Analyst Price Target

$62.60
89.93% Upside
High Prediction$77.00
Average Prediction$62.60
Low Prediction$38.00
TypeCurrent
6/9/22 to 6/9/23
1 Month Ago
5/10/22 to 5/10/23
3 Months Ago
3/11/22 to 3/11/23
1 Year Ago
6/9/21 to 6/9/22
Consensus Rating
Moderate Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$62.60$64.63$65.86$49.00
Predicted Upside89.93% Upside97.70% Upside98.41% Upside84.98% Upside
Get DICE Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DICE and its competitors with MarketBeat's FREE daily newsletter.


DICE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DICE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

DICE Therapeutics Stock vs. The Competition

TypeDICE TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.91
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside91.97% Upside1,164.32% Upside250.13% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/24/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageEqual Weight$38.00+11.40%
5/22/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$71.00+117.39%
3/31/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$56.00+95.33%
3/16/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$60.00+103.32%
3/1/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
3/1/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
3/1/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
11/15/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$65.00+95.61%
10/11/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$34.00 ➝ $62.00+56.68%
10/11/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Thomas Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$46.00 ➝ $77.00+92.93%
10/11/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Agrawal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$36.00 ➝ $68.00+72.85%
10/11/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$45.00 ➝ $75.00+90.65%
10/11/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$37.00 ➝ $54.00+37.26%
(Data available from 6/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












DICE Price Target - Frequently Asked Questions

What is DICE Therapeutics's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for DICE Therapeutics stock is Moderate Buy based on the current 1 hold rating and 10 buy ratings for DICE. The average twelve-month price prediction for DICE Therapeutics is $62.60 with a high price target of $77.00 and a low price target of $38.00. Learn more on DICE's analyst rating history.

Do Wall Street analysts like DICE Therapeutics more than its competitors?

Analysts like DICE Therapeutics more than other Medical companies. The consensus rating for DICE Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how DICE compares to other companies.

Does DICE Therapeutics's stock price have much upside?

According to analysts, DICE Therapeutics's stock has a predicted upside of 90.60% based on their 12-month price targets.

What analysts cover DICE Therapeutics?

DICE Therapeutics has been rated by Canaccord Genuity Group, HC Wainwright, Needham & Company LLC, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:DICE) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -